PapersFlow Research Brief
Bone health and osteoporosis research
Research Guide
What is Bone health and osteoporosis research?
Bone health and osteoporosis research is the scientific study of prevention, diagnosis, and treatment of osteoporosis, focusing on fractures, bone mineral density, microstructure, and effects of medications and signaling pathways on bone health.
This field encompasses 94,617 works addressing skeletal disorders through analysis of bone mineral density and microstructure. Key interventions include vitamin D supplementation and drugs like parathyroid hormone (1-34), denosumab, and zoledronic acid. Research also examines signaling pathways such as Wnt signaling and sclerostin in bone turnover.
Topic Hierarchy
Research Sub-Topics
Bone Mineral Density Measurement
Researchers study dual-energy X-ray absorptiometry (DXA) techniques, reference standards, and factors influencing BMD accuracy in osteoporosis diagnosis. Longitudinal studies assess BMD changes with age, menopause, and interventions.
Antiresorptive Therapies Osteoporosis
Investigates bisphosphonates like zoledronic acid and denosumab effects on bone turnover markers, fracture reduction, and long-term safety profiles. Clinical trials compare efficacy across patient subgroups.
Anabolic Agents Bone Formation
Examines parathyroid hormone analogs and emerging sclerostin inhibitors for stimulating bone formation and microstructure improvements. Studies address intermittent dosing regimens and combination therapies.
Osteoporotic Fracture Epidemiology
Analyzes incidence, prevalence, economic costs, and risk factors for hip, vertebral, and non-hip fractures using population cohorts. Projections model future burdens with aging demographics.
Vitamin D Calcium Supplementation
Evaluates supplementation guidelines, deficiency thresholds, and impacts on bone health outcomes in diverse populations. Meta-analyses assess fracture risk reduction and optimal dosing.
Why It Matters
Osteoporosis research directly impacts clinical management of fractures, a major health burden with over 2 million incident cases costing nearly $17 billion in the United States in 2005, projected through 2025 (Burge et al., 2006, 'Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025'). Guidelines from Holick et al. (2011) in 'Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline' recommend supplementation levels based on age to address widespread deficiency affecting skeletal health. Neer et al. (2001) demonstrated in 'Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis' that 40-microg doses reduced vertebral and nonvertebral fracture risk while increasing bone mineral density. These findings guide treatments in orthopedics, reducing disability from osteoporotic fractures estimated worldwide by Johnell and Kanis (2006) in 'An estimate of the worldwide prevalence and disability associated with osteoporotic fractures'.
Reading Guide
Where to Start
Start with 'Vitamin D Deficiency' by Holick (2007) because it provides foundational knowledge on a common, modifiable risk factor central to bone health across all ages.
Key Papers Explained
Holick (2007) 'Vitamin D Deficiency' establishes deficiency prevalence, which Holick et al. (2011) 'Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline' builds into supplementation guidelines; Neer et al. (2001) 'Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis' demonstrates anabolic therapy outcomes; Klibanski (2001) 'Osteoporosis Prevention, Diagnosis, and Therapy' offers diagnostic frameworks; these connect through shared emphasis on risk factors and interventions validated by Cosman et al. (2014) 'Clinician’s Guide to Prevention and Treatment of Osteoporosis'.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to standardize tools like µCT for microstructure per Bouxsein et al. (2010) 'Guidelines for assessment of bone microstructure in rodents using micro–computed tomography', with applications to fracture prediction. Economic modeling from Burge et al. (2006) informs policy amid stable 94,617 works count.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Vitamin D Deficiency | 2007 | New England Journal of... | 13.3K | ✕ |
| 2 | Evaluation, Treatment, and Prevention of Vitamin D Deficiency:... | 2011 | The Journal of Clinica... | 10.2K | ✓ |
| 3 | How useful is SBF in predicting in vivo bone bioactivity? | 2006 | Biomaterials | 9.2K | ✕ |
| 4 | Osteoporosis Prevention, Diagnosis, and Therapy | 2001 | JAMA | 5.4K | ✕ |
| 5 | An estimate of the worldwide prevalence and disability associa... | 2006 | Osteoporosis Internati... | 4.6K | ✕ |
| 6 | Effect of Parathyroid Hormone (1-34) on Fractures and Bone Min... | 2001 | New England Journal of... | 4.5K | ✕ |
| 7 | Guidelines for assessment of bone microstructure in rodents us... | 2010 | Journal of Bone and Mi... | 4.3K | ✓ |
| 8 | Clinician’s Guide to Prevention and Treatment of Osteoporosis | 2014 | Osteoporosis Internati... | 4.0K | ✓ |
| 9 | The 2011 Report on Dietary Reference Intakes for Calcium and V... | 2010 | The Journal of Clinica... | 4.0K | ✓ |
| 10 | Incidence and Economic Burden of Osteoporosis-Related Fracture... | 2006 | Journal of Bone and Mi... | 4.0K | ✕ |
Frequently Asked Questions
What role does vitamin D deficiency play in bone health?
Vitamin D deficiency is common and affects skeletal and nonskeletal health, despite food fortification reducing rickets (Holick, 2007, 'Vitamin D Deficiency'). It contributes to osteoporosis by impairing bone mineralization. Supplementation is recommended at levels depending on age and circumstances (Holick et al., 2011, 'Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline').
How does parathyroid hormone (1-34) treat osteoporosis?
Parathyroid hormone (1-34) decreases vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis (Neer et al., 2001, 'Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis'). The 40-microg dose increases vertebral, femoral, and total-body bone mineral density more than the 20-microg dose. It is well tolerated as a treatment option.
What are standard methods for assessing bone microstructure?
Micro-computed tomography (µCT) evaluates trabecular and cortical bone morphology in rodents (Bouxsein et al., 2010, 'Guidelines for assessment of bone microstructure in rodents using micro–computed tomography'). Guidelines standardize image acquisition, evaluation, and reporting across systems. This addresses variations in commercial µCT approaches.
What is the economic impact of osteoporotic fractures?
In 2005, the United States had over 2 million osteoporosis-related fractures costing nearly $17 billion (Burge et al., 2006, 'Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025'). Men account for more than 25% of the burden. Projections extend to 2025 by age, sex, race, and fracture type.
What do clinical guidelines recommend for osteoporosis prevention?
Osteoporosis prevention involves identifying risks across populations, as it affects all ages and groups (Klibanski, 2001, 'Osteoporosis Prevention, Diagnosis, and Therapy'). Clinicians should follow updated guides like Cosman et al. (2014) in 'Clinician’s Guide to Prevention and Treatment of Osteoporosis'. Calcium and vitamin D intakes are specified by the Institute of Medicine (Ross et al., 2010, 'The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know').
Open Research Questions
- ? How can µCT standardization be extended beyond rodents to human bone microstructure assessment?
- ? What are the long-term effects of parathyroid hormone (1-34) versus bisphosphonates like zoledronic acid on fracture prevention?
- ? To what extent does Wnt signaling modulation via sclerostin inhibitors improve bone mineral density in diverse populations?
- ? How do interactions between vitamin D, parathyroid hormone, and bone turnover markers predict osteoporotic fracture risk?
- ? What microstructural changes distinguish osteoporotic fractures from other bone pathologies?
Recent Trends
The field maintains 94,617 works with no reported 5-year growth data.
Established papers like Holick et al. and Cosman et al. (2014) guide vitamin D and treatment protocols.
2011No recent preprints or news in the last 12 months indicate steady reliance on validated interventions such as parathyroid hormone and denosumab.
Research Bone health and osteoporosis research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bone health and osteoporosis research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers